AirSculpt Technologies Stock (NASDAQ: AIRS)

Dernières nouvelles pour AirSculpt Technologies (NASDAQ:AIRS) Stock

AirSculpt Technologies

AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies Inc

AirSwap - United States Dollar

Airship AI Holdings, Inc - Class A Common Stock

Airship AI Holdings Inc

Airspan Networks Holdings Inc

Airspan Networks Holdings Inc Warrants (01/11/2026)

Airspan Networks Holdings Inc Warrants - Class C (01/11/2026)

WIIM

ATXG

Addentax Group shares are trading higher after the company announced it will acquire 8,000 Bitcoins and other cryptocurrencies, including Official Trump.

Scotiabank analyst Greg McGinniss maintains Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) with a Sector Perform and lowers the price target from $56 to $50.

News

Price Target

Analyst Ratings

LINE

Scotiabank Maintains Sector Perform on Lineage, Lowers Price Target to $50

ISSC

Innovative Solutions shares are trading higher after the company reported better-than-expected Q2 financial results.

KLTO

Klotho Neurosciences shares are trading lower. The company reported Q1 EPS results.

<a href="https://www.bloomberg.com/news/articles/2025-05-15/senators-revive-bill-to-break-big-tech-s-grip-on-pentagon-deals" title="https://www.bloomberg.com/news/articles/2025-05-15/senators-revive-bill-to-break-big-tech-s-grip-on-pentagon-deals">https://www.bloomberg.com/news/articles/2025-05-15/senators-revive-bill-to-break-big-tech-s-grip-on-pentagon-deals</a>

Macro Economic Events

Politics

Global

Economics

General

AMZN

GOOG

GOOGL

MSFT

'Senators Revive Bill To Break Big Tech's Grip On Pentagon Deals' - Bloomberg News

B of A Securities analyst Craig Siegenthaler downgrades Virtu Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) from Buy to Neutral and maintains the price target from $43 to $43.

Downgrades

VIRT

B of A Securities Downgrades Virtu Finl to Neutral, Maintains Price Target to $43

Trading Ideas

New Fortress Energy Shares Halted On Circuit Breaker To The Downside, Stock Now Down 58.4%

<ul>
<li>Term sheet with Universal Capital, LLC to fund HOPE Therapeutics clinic acquisition strategy</li>
<li>Funding tied to already-announced acquisitions, with additional&nbsp;tranches contemplated for further growth, subject to standard due diligence</li>
<li>Together with previously announced term sheet with a strategic investor, HOPE funding of $10.3 million is planned in the near term&nbsp;</li>
</ul>
MIAMI, May 15, 2025 /PRNewswire/ --&nbsp;HOPE Therapeutics&#x2122;, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>), a clinical-stage biopharmaceutical company, today announced signing of a term sheet with Universal Capital, LLC ("Universal") to provide $7.8 million in acquisition capital to initiate HOPE's planned national rollup of interventional psychiatry clinics, commencing with previously-announced acquisitions of Dura Medical, Kadima, and NeuroSpa. Together with proceeds of a previously announced strategic investment, this financing is anticipated to provide $10.3 million in acquisition capital.

Financing

NRXP

NRx Pharmaceuticals' HOPE Therapeutics Announces Signing Of Term Sheet For $7.8M Debt Financing To Fuel HOPE Clinic Acquisitions; Financing Is Anticipated To Provide $10.3M In Acquisition Capital

BMO Capital analyst Keith Bachman maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Outperform and raises the price target from $60 to $63.

BMO Capital Maintains Outperform on Dynatrace, Raises Price Target to $63

Scotiabank analyst Orest Wowkodaw maintains Ivanhoe Mines (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IVN#TSX">IVN</a>) with a Sector Outperform and raises the price target from C$18.5 to C$19.

TSX:IVN

Scotiabank Maintains Sector Outperform on Ivanhoe Mines, Raises Price Target to C$19

SILO

Silo Pharma shares are trading lower after the company announced the pricing of a $2 million public offering of 3,333,338 shares and series A-1 Warrants at a combined public offering price of $0.60 per share and associated Series A-1 Warrants.

Watching Deere & Co.; During Conf Call, CEO Reportedly Says Prepared To Invest $20B In U.S. Over Next Decade; Exec Says Global Uncertainty Continues To Weigh On Customer Sentiment; Economic Uncertainty, High Interest Rates Pressuring Order Activity For Construction Equipment

ANTA

ANTA stock has given up its prior gain. Antalpha Platform shares were trading higher amid possible continued strength after its initial public offering took place Wednesday.

On a past episode of "<a href="https://www.tiktok.com/@daveramsey/video/7501324721934372138">The Ramsey Show</a>," personal finance expert Dave Ramsey took a call from a listener facing a daunting financial reality: $430,000 in student loan debt and no degree to show for it.
The caller, 34-year-old James from Lexington, Kentucky, had pursued a career in medicine but was dismissed from medical school after failing two licensing exams. His story is a cautionary tale about the long-term consequences of <a href="https://www.benzinga.com/25/05/45260074/student-loan-debt-hits-1-77-trillion-dave-ramsey-blames-parents-not-policies-its-not-a-student-loan-crisis-we-have-a-parenting-crisis">student loans</a> — and the high cost of an unfinished degree.
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
<h2 class="wp-block-heading">From Med School Dreams to Financial Distress</h2>
James explained that roughly $80,000 of his debt came from undergraduate studies and pre-med coursework. The remaining balance — over $350,000 — was tied to his time in medical school. Despite making it through the first few years of the program, he struggled to pass the board exams required to move forward and was ultimately dismissed.
"I have the debt, but no degree that I was planning to use to actually be able to pay that back," James said.
<a href="https://www.benzinga.com/25/05/45332474/a-38-year-old-father-shares-how-he-paid-388000-in-debt-after-listening-to-dave-ramsey-we-held-off-on-a-lot-of-big-purchases">Ramsey</a> didn't hold back. "You&#8217;re right, that&#8217;s a mess," he said, expressing concern over the scale of the debt and the difficult road ahead.
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
<h2 class="wp-block-heading">Exploring Career Options  —  But More Debt Looms</h2>
Since leaving medical school, James started working as a substitute teacher and quickly moved into teaching high school biology. While grateful to be employed, he admitted that the job wasn't enough to tackle such a large debt burden.
He said he had looked into other healthcare roles — like becoming a physician assistant — but those paths would require additional classes, years of training, and another $60,000 to $70,000 in loans.
Ramsey suggested exploring career options in the medical field that would allow James to earn a six-figure salary without accumulating even more debt. "I want to move you well beyond high school biology teacher to pay off $430,000 in debt," he said.&nbsp;
One possible strategy: find a hospital or healthcare organization that offers student loan repayment as part of a hiring package.
See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
<h2 class="wp-block-heading">‘You've Got Time' — But Action Is Urgent</h2>
James also shared that he had no retirement savings, though he did have an emergency fund. Ramsey urged him not to panic about before he had a solid income.
"We gotta address your career track, which gets you to your income, which solves the debt problem, and then solves the retirement problem," Ramsey said. "If you were 66, I might be [worried], but you're not. You got time to work through that."
Still, the urgency was clear. Ramsey emphasized that without a solid income, debt repayment — and <a href="https://www.benzinga.com/personal-finance/25/03/44504769/suze-orman-says-owning-a-house-is-not-a-retirement-plan-heres-how-to-build-true-financial-security-with-smart-diversification">financial security</a> — would remain out of reach.
<h2 class="wp-block-heading">A Hard Lesson for Others</h2>
While James's story is uniquely painful, it sheds light on a broader issue: the high cost of education and the risk of taking on large debt without a guaranteed return. Ramsey's advice highlights the importance of career planning, especially when large loans are involved.
For those considering graduate or professional school, Ramsey's message is clear: know your path, count the costs, and be sure the investment has a clear payoff on the other side.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Dave Ramsey Reacts To $430K In Student Loans Without A Degree: 'You're Right, That's A Mess'

Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) has outperformed the market over the past 5 years by 3.66% on an annualized basis producing an average annual return of 18.62%. Currently, Marvell Tech has a market capitalization of $55.67 billion. 
Buying $100 In MRVL: If an investor had bought $100 of MRVL stock 5 years ago, it would be worth $233.10 today based on a price of $64.28 for MRVL at the time of writing.
<h3>Marvell Tech's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747318511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MRVL

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

LOBO

LOBO EV TECHNOLOGIES shares are trading higher after the company announced it reached a $6 million agreement to supply 5,000 electric vehicles to the US market.

BMO Capital analyst Ameet Thakkar maintains NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Market Perform and raises the price target from $51 to $59.

BMO Capital Maintains Market Perform on NEXTracker, Raises Price Target to $59

XPeng Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) <a href="https://www.benzinga.com/pressreleases/25/05/g45428475/xpeng-unveils-first-images-of-next-generation-p7-sports-sedan-designed-by-rafik-ferrag" target="_blank" rel="noreferrer noopener">released the official images</a> of its new electric sports sedan XPENG P7 on Thursday.
Lead exterior designer Rafik Ferrag published the images of the new car, previously known as E29. The French designer, known for shaping the first-generation P7 in 2018, leads the creative vision behind this latest iteration.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45348699/us-listed-chinese-stocks-rally-as-countries-agree-to-ease-import-tariffs" rel="noreferrer noopener">US Listed Chinese Stocks Rally As Countries Agree To Ease Import Tariffs</a>
The new XPENG P7 is a 5-seater sports sedan that XPeng&#8217;s research and development team developed over five years.
CEO He Xiaopeng describes it as a significant upgrade that blends AI-powered luxury, cutting-edge XPENG Turing Smart Driving, and an immersive smart cockpit.
XPeng has rapidly expanded across Asia, Australia, and Europe, with operations in more than 30 countries and regions.
Xpeng stock has surged over 81% year-to-date. In April, XPeng delivered <a href="https://www.benzinga.com/25/05/45134925/chinese-ev-companies-see-huge-april-growth-xpeng-surges-273-in-deliveries" target="_blank" rel="noreferrer noopener">35,045 Smart EVs</a>, marking a 273% increase and surpassing 30,000 units for the sixth consecutive month. Cumulative deliveries of XPeng MONA M03 had surpassed 100,000 units. The XPeng P7+ achieved its 50,000th vehicle production milestone in five months since its launch. For the first four months of 2025, XPeng delivered 129,053 Smart EVs, representing a 313% increase.
In April, XPeng made the&nbsp;global debut of its 2025 XPeng X9 model&nbsp;and a roadmap that connects smart EVs, flying cars, and humanoid robots under its AI Tech Tree platform.
XPeng&#8217;s homegrown Turing AI chip, which underpins products including autonomous vehicles and robotic platforms, is scheduled for mass production in mainland China by mid-2025. The AEROHT Land Aircraft Carrier, a modular flying vehicle, is expected to enter production in 2026.
The company also unveiled&nbsp;&#8220;IRON,&#8221; a humanoid robot.
XPeng debuted the X9 model. &nbsp;XPeng is preparing its Kunpeng Super Electric System for mass rollout by late 2025.
Price Actions: XPEV stock is down 1.87% at $20.52 premarket at the last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45417156/nvidia-amd-stocks-climb-as-trump-plans-to-ease-ai-chip-export-rules" target="_blank" rel="noreferrer noopener">Nvidia, AMD And Other Chip Stocks Gain As Trump Plans To Ease AI Chip Export Rules</a></li>
</ul>
Photo: Shutterstock

XPEV

XPeng Unveils New AI-Powered Sports EV With Smart Driving And Luxury Tech

Scotiabank analyst Kevin Krishnaratne maintains Dye &amp; Durham (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DND#TSX">DND</a>) with a Sector Outperform and lowers the price target from C$18 to C$14.

TSX:DND

Scotiabank Maintains Sector Outperform on Dye & Durham, Lowers Price Target to C$14

NanoVibronix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the pricing of an underwritten public offering of approximately 400,000 shares of the Company's Series G Convertible Preferred Stock ("Preferred Stock"), par value $0.001 per share and Warrants to purchase up to 4,901,961 shares of common stock, par value $0.001 per share (the "Common Stock") of the Company at an exercise price of $2.04 per share (the "Warrants"). The combined public offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00. The closing of the public offering is expected to occur on or about May 19, 2025, subject to the satisfaction of customary closing conditions.
Dawson James Securities, Inc. is acting as the sole bookrunning manager for the public offering.
The gross proceeds of the public offering are expected to be approximately $10 million before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for (i) the redemption of the principal amount of its outstanding debenture with an aggregate principal amount of $1,300,000, initially issued on February 14, 2025, pursuant to the terms and conditions of such debenture and up to $700,000 to be applied to the partial repayment of an outstanding note issued on January 17, 2025, in the aggregate principal amount of $2,497,308 and (ii) general corporate purposes.

Offerings

NAOV

Reported Earlier: NanoVibronix Prices $10M Public Offering Of 400K Shares Of Series G Convertible Preferred Stock And Warrants To Purchase 4.9M Common Shares At $2.04 Each

Press Releases

AirSculpt Technologies Announces Preliminary Third Quarter 2024 Revenue Results

Earnings

AirSculpt Technologies Reports Third Quarter Fiscal 2024 Results

AirSculpt® Technologies, Inc. Announces Opening of Its New White Plains, NY Center

Management

AirSculpt Technologies Names Yogi Jashnani Chief Executive Officer

AirSculpt Technologies Announces Participation in the ICR Conference 2025

AirSculpt Technologies Updates Fiscal Year 2024 Guidance in Advance of its Participation in the ICR Conference 2025

AirSculpt Technologies Announces Fourth Quarter Fiscal 2024 Earnings Release Date and Conference Call

AirSculpt Technologies Reports Fourth Quarter, and Full Year Fiscal 2024 Results

AirSculpt Technologies Announces First Quarter Fiscal 2025 Earnings Release Date and Conference Call

AirSculpt Technologies Reports First Quarter Fiscal 2025 Results and Full Year Guidance

AIRS

AMN Healthcare Services

American Shared Hospital Services Common Stock

American Shared Hospital

Biodesix

Basel Medical Group Ltd - ordinary shares

Basel Medical Group

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

AirSculpt Technologies

Actualités

Dernières nouvelles pour AirSculpt Technologies (NASDAQ:AIRS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL